Toll Free: 1-888-928-9744

H1N1 Infection - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 203 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

H1N1 Infection - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'H1N1 Infection - Pipeline Review, H1 2016', provides an overview of the H1N1 Infection pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for H1N1 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H1N1 Infection and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
- The report reviews pipeline therapeutics for H1N1 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved H1N1 Infection therapeutics and enlists all their major and minor projects
- The report assesses H1N1 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for H1N1 Infection

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 H1N1 Infection Overview 9 Therapeutics Development 10 Pipeline Products for H1N1 Infection - Overview 10 Pipeline Products for H1N1 Infection - Comparative Analysis 11 H1N1 Infection - Therapeutics under Development by Companies 12 H1N1 Infection - Therapeutics under Investigation by Universities/Institutes 16 H1N1 Infection - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 H1N1 Infection - Products under Development by Companies 20 H1N1 Infection - Products under Investigation by Universities/Institutes 23 H1N1 Infection - Companies Involved in Therapeutics Development 24 Adamas Pharmaceuticals, Inc. 24 Akshaya Bio Inc. 25 Altimmune, Inc. 26 Antigen Express, Inc. 27 Beijing Minhai Biotechnology Co., Ltd 28 CEL-SCI Corporation 29 Cilian AG 30 CSL Limited 31 EpiVax, Inc. 32 Etubics Corporation 33 Gemmus Pharma Inc. 34 iBio, Inc. 35 ILiAD Biotechnologies, LLC 36 Inovio Pharmaceuticals, Inc. 37 Johnson & Johnson 38 Kineta, Inc. 39 Kyowa Hakko Kirin Co., Ltd. 40 Medicago Inc. 41 MedImmune, LLC 42 Microbiotix, Inc. 43 Mucosis B.V. 44 NanoViricides, Inc. 45 NewLink Genetics Corporation 46 Novavax, Inc. 47 OPKO Health, Inc. 48 PeptiDream Inc. 49 Sarepta Therapeutics, Inc. 50 Sirnaomics, Inc. 51 Takeda Pharmaceutical Company Limited 52 TechnoVax, Inc. 53 Theraclone Sciences, Inc. 54 Touchlight Genetics Limited 55 United Therapeutics Corporation 56 Vaxart, Inc. 57 Vironova AB 58 Visterra, Inc. 59 Zydus Cadila Healthcare Limited 60 H1N1 Infection - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 65 Assessment by Route of Administration 67 Assessment by Molecule Type 69 Drug Profiles 71 A-06 - Drug Profile 71 ADS-324 - Drug Profile 72 AEA-35p - Drug Profile 73 Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile 74 Aspidasept - Drug Profile 75 C-05 - Drug Profile 76 CiFlu - Drug Profile 77 CR-9114 - Drug Profile 79 diridavumab - Drug Profile 80 Fludase - Drug Profile 82 FluGEM - Drug Profile 84 FVH-1 - Drug Profile 86 Gamma-Flu - Drug Profile 87 GP-1001 - Drug Profile 88 GP-1681 - Drug Profile 89 GREFLU/CAL - Drug Profile 91 H1N1 [A/Aichi/2/68] vaccine - Drug Profile 92 HB-36.6 - Drug Profile 93 Human Antibody Based Vaccines - Drug Profile 94 iHA-24 - Drug Profile 96 infectious vaccine - Drug Profile 97 Influ-nRNA - Drug Profile 98 influenza [serotype A] vaccine - Drug Profile 99 influenza [strain A/H1N1] vaccine - Drug Profile 100 influenza [strain A/H1N1] vaccine - Drug Profile 102 influenza [strain A/H1N1] vaccine - Drug Profile 103 influenza [strain H1N1] (monovalent) vaccine - Drug Profile 104 influenza [strain H1N1] (mutivalent) vaccine - Drug Profile 105 influenza [strain H1N1] vaccine - Drug Profile 106 influenza [strain H1N1] vaccine - Drug Profile 107 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 108 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 109 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 110 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 111 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 112 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 113 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 115 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 116 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 118 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 120 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 121 influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 122 influenza vaccine - Drug Profile 123 influenza vaccine - Drug Profile 125 INO-3510 - Drug Profile 126 JNJ-872 - Drug Profile 127 LEAPS-H1N1-DC - Drug Profile 129 MBX-2329 - Drug Profile 130 MBX-2546 - Drug Profile 132 NEO-8877 - Drug Profile 133 NVINF-1 - Drug Profile 134 NVINF-2 - Drug Profile 136 pertussis [strain BPZE1] vaccine - Drug Profile 137 PNSIA-28 - Drug Profile 139 PNSIA-49 - Drug Profile 140 radavirsen - Drug Profile 141 Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile 143 RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile 144 Small Molecules for RSV and Influenza A Infections - Drug Profile 145 Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile 146 Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 147 Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile 149 STP-702 - Drug Profile 150 Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 151 TCN-032 - Drug Profile 152 TVX-002 - Drug Profile 154 VH-244 - Drug Profile 155 VIS-410 - Drug Profile 157 VNFC-045 - Drug Profile 159 VNFC-051 - Drug Profile 160 VXAA-1.1 - Drug Profile 161 Z-3G1 - Drug Profile 162 H1N1 Infection - Recent Pipeline Updates 163 H1N1 Infection - Dormant Projects 183 H1N1 Infection - Discontinued Products 187 H1N1 Infection - Product Development Milestones 188 Featured News & Press Releases 188 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 197 Disclaimer 198
List of Tables
Number of Products under Development for H1N1 Infection, H1 2016 15 Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2016 16 Number of Products under Development by Companies, H1 2016 18 Number of Products under Development by Companies, H1 2016 (Contd..1) 19 Number of Products under Development by Companies, H1 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Comparative Analysis by Late Stage Development, H1 2016 22 Comparative Analysis by Clinical Stage Development, H1 2016 23 Comparative Analysis by Early Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Investigation by Universities/Institutes, H1 2016 28 H1N1 Infection - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 29 H1N1 Infection - Pipeline by Akshaya Bio Inc., H1 2016 30 H1N1 Infection - Pipeline by Altimmune, Inc., H1 2016 31 H1N1 Infection - Pipeline by Antigen Express, Inc., H1 2016 32 H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 33 H1N1 Infection - Pipeline by CEL-SCI Corporation, H1 2016 34 H1N1 Infection - Pipeline by Cilian AG, H1 2016 35 H1N1 Infection - Pipeline by CSL Limited, H1 2016 36 H1N1 Infection - Pipeline by EpiVax, Inc., H1 2016 37 H1N1 Infection - Pipeline by Etubics Corporation, H1 2016 38 H1N1 Infection - Pipeline by Gemmus Pharma Inc., H1 2016 39 H1N1 Infection - Pipeline by iBio, Inc., H1 2016 40 H1N1 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 41 H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 42 H1N1 Infection - Pipeline by Johnson & Johnson, H1 2016 43 H1N1 Infection - Pipeline by Kineta, Inc., H1 2016 44 H1N1 Infection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 45 H1N1 Infection - Pipeline by Medicago Inc., H1 2016 46 H1N1 Infection - Pipeline by MedImmune, LLC, H1 2016 47 H1N1 Infection - Pipeline by Microbiotix, Inc., H1 2016 48 H1N1 Infection - Pipeline by Mucosis B.V., H1 2016 49 H1N1 Infection - Pipeline by NanoViricides, Inc., H1 2016 50 H1N1 Infection - Pipeline by NewLink Genetics Corporation, H1 2016 51 H1N1 Infection - Pipeline by Novavax, Inc., H1 2016 52 H1N1 Infection - Pipeline by OPKO Health, Inc., H1 2016 53 H1N1 Infection - Pipeline by PeptiDream Inc., H1 2016 54 H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016 55 H1N1 Infection - Pipeline by Sirnaomics, Inc., H1 2016 56 H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 57 H1N1 Infection - Pipeline by TechnoVax, Inc., H1 2016 58 H1N1 Infection - Pipeline by Theraclone Sciences, Inc., H1 2016 59 H1N1 Infection - Pipeline by Touchlight Genetics Limited, H1 2016 60 H1N1 Infection - Pipeline by United Therapeutics Corporation, H1 2016 61 H1N1 Infection - Pipeline by Vaxart, Inc., H1 2016 62 H1N1 Infection - Pipeline by Vironova AB, H1 2016 63 H1N1 Infection - Pipeline by Visterra, Inc., H1 2016 64 H1N1 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 65 Assessment by Monotherapy Products, H1 2016 66 Assessment by Combination Products, H1 2016 67 Number of Products by Stage and Target, H1 2016 69 Number of Products by Stage and Mechanism of Action, H1 2016 71 Number of Products by Stage and Route of Administration, H1 2016 73 Number of Products by Stage and Molecule Type, H1 2016 75 H1N1 Infection Therapeutics - Recent Pipeline Updates, H1 2016 168 H1N1 Infection - Dormant Projects, H1 2016 188 H1N1 Infection - Dormant Projects (Contd..1), H1 2016 189 H1N1 Infection - Dormant Projects (Contd..2), H1 2016 190 H1N1 Infection - Dormant Projects (Contd..3), H1 2016 191 H1N1 Infection - Discontinued Products, H1 2016 192


List of Figures
Number of Products under Development for H1N1 Infection, H1 2016 15 Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Comparative Analysis by Late Stage Development, H1 2016 22 Comparative Analysis by Clinical Stage Development, H1 2016 23 Comparative Analysis by Early Stage Products, H1 2016 24 Assessment by Monotherapy Products, H1 2016 66 Assessment by Combination Products, H1 2016 67 Number of Products by Top 10 Targets, H1 2016 68 Number of Products by Stage and Top 10 Targets, H1 2016 68 Number of Products by Top 10 Mechanism of Actions, H1 2016 70 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 70 Number of Products by Routes of Administration, H1 2016 72 Number of Products by Stage and Routes of Administration, H1 2016 72 Number of Products by Top 10 Molecule Types, H1 2016 74 Number of Products by Stage and Top 10 Molecule Types, H1 2016 74

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify